COVID-19 Treatment, Testing Costs Could Reach $417 Billion Over Next Year

With the novel coronavirus spreading across the nation, both private health insurers and public payers could see heavy economic costs. According to a recent paper prepared by Wakely Consulting Group on behalf of America’s Health Insurance Plans, under the baseline risk scenario with a U.S. infection rate of 20%, allowed costs could range from $112.5 billion to $185.4 billion over 2020 and 2021 combined. As the ultimate number and severity of COVID-19 cases remain unknown, the estimates have a wide range. Graphics below highlight three different organizations’ estimates for how the pandemic will change U.S. health care costs.

0 Comments
© 2022 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

person-holding-a-pencil
September 30

Medicaid Plans Aren’t Properly Reporting MLR Data, OIG Finds

READ MORE
stethoscope-bill-and-pills
September 30

How Would Adjusting the Marketplace Coverage Benchmark to a Gold Plan Affect Affordability?

READ MORE
department-of-justice-building
September 30

Loss in UnitedHealth/Change Trial May Not Lower DOJ’s Deal-Blocking Appetite

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today